Journal
TRENDS IN MOLECULAR MEDICINE
Volume 26, Issue 5, Pages 435-437Publisher
CELL PRESS
DOI: 10.1016/j.molmed.2020.03.006
Keywords
-
Ask authors/readers for more resources
A recent study by Dvorak et al. supports metabolite mimicry as a drug development strategy. A potent agonist of the human pregnane X receptor (hPXR) was designed from two ligands that are products of the microbial catabolism of tryptophan. Its validity was demonstrated in cellular assays and a murine colitis model expressing hPXR by a significant reduction in inflammation biomarkers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available